Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.37 |
| ▸ | ADH1B | P00325 | 2/20 | 0.37 |
| ▸ | ADH1C | P00326 | 2/20 | 0.37 |
| ▸ | ADH1A | P07327 | 2/20 | 0.37 |
| ▸ | ADH7 | P40394 | 2/20 | 0.37 |
| ▸ | ADH4 | P08319 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5055068 | 0.78 | CYP2D6 (0.61) | CYP1A2CYP2C19FAAHALDH1A1SMN1; SMN2 | |
| SCHEMBL2363781 | 0.77 | FAAH (0.50) | CYP1A2CYP2C19FAAHALDH1A1LMNA | |
| SCHEMBL1566733 | 0.77 | FAAH (0.50) | CYP1A2CYP2C19FAAHALDH1A1LMNA | |
| SCHEMBL17674145 | 0.73 | CYP1A2 (0.54) | CYP1A2CYP2C19FAAHALDH1A1LMNA | |
| SCHEMBL14706091 | 0.73 | CYP1A2 (0.54) | CYP1A2CYP2C19FAAHALDH1A1LMNA | |
| SCHEMBL17674143 | 0.73 | CYP1A2 (0.54) | CYP1A2CYP2C19FAAHALDH1A1LMNA | |
| SCHEMBL3956082 | 0.71 | ALDH1A1 (0.43) | FAAHALDH1A1LMNASMN1; SMN2CYP2D6 | |
| SCHEMBL23941092 | 0.71 | CYP1A2 (0.51) | CYP1A2CYP2C19FAAHALDH1A1LMNA | |
| SCHEMBL14692671 | 0.71 | FAAH (0.42) | FAAHEPHX1MGLL | |
| SCHEMBL28944281 | 0.71 | EPHX1 (0.45) | CYP1A2FAAHALDH1A1SMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978751-B1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-12-05 | — | — | EP | disclosed |
| US-9738655-B2 | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160145263-A1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-26 | — | — | US | disclosed |
| EP-2978751-A1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014160668-A1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145263-A1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | TFPI2, TFPI, F12 | CYP1A2 343/4885CYP2C19 448/4885FAAH 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.